miRNAs in High Grade Serous Ovarian Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2023-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High grade serous ovarian cancer represents the gynecological malignancy with the highest incidence of mortality. Decision-making tools are currently limited to the use of standard imaging modalities and analysis of serum biomarkers, such as CA 125, which often have low specificity and sensitivity. Recently, a growing research interest has been aimed at so-called circulating microRNAs (miRNAs). Indeed, it has been observed that miRNAs are abundantly present in all biological fluids and play the key role of messengers in intercellular communication. Cancer cells have a rapid turnover which results in a continuous release of nucleic acids and vesicles derived from the tumor itself, such as the tumor cells themselves that separate from the tumor mass to enter the bloodstream. Given their important role as modulators of gene expression, in order to preserve their integrity, miRNAs are encapsulated in specific vesicles, in order to prevent their degradation by the enzymes present in biological fluids. In this context, the chance of monitoring the expression levels of specific miRNAs represents a very interesting option both for an early diagnosis and for monitoring the clinical response to pharmacological treatment. Currently, there are no non-invasive approaches to monitor the clinical outcome in real time, while the identification of circulating biomarkers would allow prompt intervention, possibly modifying the pharmacological management in case of progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of miRNA Expression in Endometrial Cancer

NCT04845425

Endometrial Cancer

UNKNOWN

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

NCT04454450

Ovarian Cancer High Grade Ovarian Serous

ACTIVE_NOT_RECRUITING NA

SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours

NCT06329323

Germ Cell Ovarian Cancer Germ Cell Tumor Germ Cell Cancer +5 more

NOT_YET_RECRUITING

miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

NCT01444560

Cutaneous Melanoma Nevi

COMPLETED

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

NCT06274541

Serous Ovarian Tumor Endometrioid Carcinoma Ovary Fallopian Tube Cancer +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Grade Serous Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age\>18
* Histological diagnosis of epithelial ovarian cancer
* Patients eligible for surgery
* Patients followed in the clinical care pathway c / o oncological gynecology (surgery and follow up)
* informed consent

Exclusion Criteria

* Patients with HCV, HBV and HIV
* Patients with other malignancies diagnosed less than 5 years prior to the diagnosis of ovarian malignancy
* Ovarian metastases of primary neoplasms of other organs
* Presence of ascites for non-neoplastic causes

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No